Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892318229> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2892318229 abstract "e15513 Background: Alpha fetoprotein (AFP)-producing gastric cancer (APGC) is a minor subtype of gastric cancer (GC) with high malignancy, rapid progress, high metastatic rate and poor prognosis. Treatment of AFP-positive GC is not different from that of AFP-negative GC, but the efficacy can not match for the latter. Apatinib, a novel inhibitor of VEGFR-2, has achieved survival improvement in advanced GC patients. We aimed to evaluate the efficacy and safety of apatinib in AFP-positive advanced gastric cancer patients. Methods: This was a single-arm, open-label, exploratory study design. Eligibility criteria included histologically proven GC; patient age 18-75 years; AFP-positive; clinical stage III or IV; and ECOG performance status of 1 or 2. A history of receiving previous treatment was not required. All the patients were orally given apatinib at an initial dose of 500 mg (qd) until disease progression or death. Dose reduction to 250 mg was allowed. Results: A total of 16 pts including 15 males and 1 female were eligible. The median age was 62.5 years (range 26-74 years). Poorly differentiated adenocarcinoma was the main histological type, and the main metastatic sites were liver (12/16) and abdominal (2/16). Ten pts received gastric surgery and 13 had previous chemotherapy prior to apatinib, and 10 patients received chemotherapy along with apatinib. Among the 16 pts, 14 were available for the efficacy evaluation. Two pts achieved partial response (PR), 10 had stable disease (SD), and 2 had progressive disease (PD). The objective response rate (ORR) and the disease control rate (DCR) were 14.3% (2/14) and 85.7% (12/14), respectively. All pts were included for safety analysis. The incidence of adverse events (AEs) was 87.5%. Main AEs were bone marrow suppression (43.75%), hypertension (50%), and abdominal pain (31.25%). Conclusions: Administration of apatinib make clinical benefit to AFP positive advanced gastric cancer with a comparable disease control and tolerable adverse reactions. Clinical trial information: ChiCTR-OPC-16008295. Clinical trial information: ChiCTR-OPC-16008295." @default.
- W2892318229 created "2018-09-27" @default.
- W2892318229 creator A5002982580 @default.
- W2892318229 creator A5026782331 @default.
- W2892318229 creator A5030221922 @default.
- W2892318229 creator A5073411731 @default.
- W2892318229 creator A5075758338 @default.
- W2892318229 date "2017-05-20" @default.
- W2892318229 modified "2023-09-23" @default.
- W2892318229 title "Clinical efficacy and safety of apatinib in treatment of alpha fetoprotein-positive advanced gastric cancer." @default.
- W2892318229 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15513" @default.
- W2892318229 hasPublicationYear "2017" @default.
- W2892318229 type Work @default.
- W2892318229 sameAs 2892318229 @default.
- W2892318229 citedByCount "0" @default.
- W2892318229 crossrefType "journal-article" @default.
- W2892318229 hasAuthorship W2892318229A5002982580 @default.
- W2892318229 hasAuthorship W2892318229A5026782331 @default.
- W2892318229 hasAuthorship W2892318229A5030221922 @default.
- W2892318229 hasAuthorship W2892318229A5073411731 @default.
- W2892318229 hasAuthorship W2892318229A5075758338 @default.
- W2892318229 hasConcept C121608353 @default.
- W2892318229 hasConcept C126322002 @default.
- W2892318229 hasConcept C143998085 @default.
- W2892318229 hasConcept C2780668389 @default.
- W2892318229 hasConcept C71924100 @default.
- W2892318229 hasConcept C90924648 @default.
- W2892318229 hasConceptScore W2892318229C121608353 @default.
- W2892318229 hasConceptScore W2892318229C126322002 @default.
- W2892318229 hasConceptScore W2892318229C143998085 @default.
- W2892318229 hasConceptScore W2892318229C2780668389 @default.
- W2892318229 hasConceptScore W2892318229C71924100 @default.
- W2892318229 hasConceptScore W2892318229C90924648 @default.
- W2892318229 hasLocation W28923182291 @default.
- W2892318229 hasOpenAccess W2892318229 @default.
- W2892318229 hasPrimaryLocation W28923182291 @default.
- W2892318229 hasRelatedWork W1879935821 @default.
- W2892318229 hasRelatedWork W1963609918 @default.
- W2892318229 hasRelatedWork W2095577289 @default.
- W2892318229 hasRelatedWork W2269709568 @default.
- W2892318229 hasRelatedWork W2373439286 @default.
- W2892318229 hasRelatedWork W2431842001 @default.
- W2892318229 hasRelatedWork W2526454245 @default.
- W2892318229 hasRelatedWork W2760679141 @default.
- W2892318229 hasRelatedWork W2769693366 @default.
- W2892318229 hasRelatedWork W2799664054 @default.
- W2892318229 hasRelatedWork W2908457113 @default.
- W2892318229 hasRelatedWork W2911868143 @default.
- W2892318229 hasRelatedWork W2948009507 @default.
- W2892318229 hasRelatedWork W2971489909 @default.
- W2892318229 hasRelatedWork W3041607941 @default.
- W2892318229 hasRelatedWork W3109122398 @default.
- W2892318229 hasRelatedWork W3156756019 @default.
- W2892318229 hasRelatedWork W3174418075 @default.
- W2892318229 hasRelatedWork W2341069781 @default.
- W2892318229 hasRelatedWork W3121645660 @default.
- W2892318229 isParatext "false" @default.
- W2892318229 isRetracted "false" @default.
- W2892318229 magId "2892318229" @default.
- W2892318229 workType "article" @default.